Trial Profile
Lenvatinib Plus Programmed Cell Death Protein-1 (PD-1) Inhibitor Versus Lenvtinib Alone for Advanced Hepatocellular Carcinoma: a Multicentre Randomised Controlled Trial
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary) ; Antineoplastics
- Indications Liver cancer
- Focus Therapeutic Use
- 30 Apr 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 05 Mar 2019 Planned initiation date changed from 21 Jan 2019 to 21 Apr 2019.
- 26 Nov 2018 Status changed from recruiting to not yet recruiting.